The Lancet in conversation with
Ein Podcast von The Lancet Group - Freitags
Kategorien:
656 Folgen
-
Crohn's disease: The Lancet: March 1, 2017
Vom: 2.3.2017 -
2030 life expectancy estimates: The Lancet: February 21, 2017
Vom: 22.2.2017 -
Religious leaders in promotion of male circumcision: The Lancet: February 14, 2017
Vom: 15.2.2017 -
Type 2 diabetes: The Lancet: February 9, 2017
Vom: 10.2.2017 -
Socioeconomic status as a risk factor for non-communicable diseases: The Lancet: January 31, 2017
Vom: 1.2.2017 -
US premature mortality: The Lancet: January 25, 2017
Vom: 26.1.2017 -
Pancreatic cancer: The Lancet: January 24, 2017
Vom: 25.1.2017 -
Use of MRI in prostate cancer screening: The Lancet: January 19, 2017
Vom: 20.1.2017 -
Amygdalar activity and cardiovascular events: The Lancet: January 12, 2017
Vom: 13.1.2017 -
Right Care Series: The Lancet: January 8, 2017
Vom: 9.1.2017 -
Ebola vaccine: The Lancet: December 22, 2016
Vom: 23.12.2016 -
Wakley Prize 2016: The Lancet: December 15, 2016
Vom: 16.12.2016 -
Breast Cancer 2016: The Lancet: December 6, 2016
Vom: 7.12.2016 -
Phantom motor execution: The Lancet: December 1, 2016
Vom: 1.12.2016 -
Multiple sclerosis Series: The Lancet: November 23, 2016
Vom: 25.11.2016 -
Where next for US health and health care?
Vom: 16.11.2016 -
The Lancet Countdown: The Lancet: November 13, 2016
Vom: 14.11.2016 -
US Election reaction: The Lancet: November 11, 2016
Vom: 11.11.2016 -
US Election: The Lancet: November 4, 2016
Vom: 4.11.2016 -
Health, equity, and women's cancers: The Lancet: November 2, 2016
Vom: 2.11.2016
Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.